Interferon in the treatment of cutaneous T-cell lymphoma.
All of the recombinant interferons are active agents for the systemic treatment of mycosis fungoides and Sézary syndrome. The response rates are similar to those observed with systemic chemotherapy. There is no clear evidence that combining interferons with other systemic therapies increases the response rates. The combination of interferon with PUVA provides provocative results. The optimal role of interferons in the treatment of mycosis fungoides and Sézary's syndrome is undefined.
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
E A
EA
Olsen
P A
PA
Bunn
D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D007372:Interferons / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins; D016899:Interferon-beta; D007371:Interferon-gamma; D007372:Interferons